We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Androgen Receptor May Impact Prostate Cancer Test

By LabMedica International staff writers
Posted on 14 Nov 2012
The study of a specific part of the male DNA makes it possible to refine the interpretation of prostate-specific antigen (PSA) tests, which could reduce the risk of men being treated for prostate cancer unnecessarily.

A PSA test measures the level of the antigen in the blood, and raised PSA can signal an increased risk of cancer; however, this is not the case for everyone. More...
The problem is that there is no reliable way to separate those with naturally high levels of PSA from those at increased risk of prostate cancer.

A study conducted at Lund University (Sweden) shows how a man's genetic characteristics can affect the androgen receptor, a protein that has an important function in the male reproductive system. It regulates the effect of testosterone and controls production of prostate-specific antigen. The study is based on samples from around 400 men from Sweden and Norway.

The scientists studied healthy men in different age groups and discovered a connection between PSA levels in the blood and DNA structure of the androgen receptor. The highest PSA levels were found in the men with the most common variant of the androgen receptor that was within the largest group of men.

Christel Björk, PhD, a doctoral student at the Department of Clinical Sciences at Lund University, said, “If we know that a man has a naturally high level of PSA, this can be taken into account in a PSA test, and the patient may be able to avoid arduous treatment with a risk of side-effects." Both the PSA level and the genetic characteristics can be identified with a blood test. Before the results can be implemented for PSA tests in the health service, the study must be repeated on a larger group.

Related Links:

Lund University



New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.